Evidence review · United States · Updated 31 Aug 2026
BPC-157: what is actually known in people?
The short answer: human evidence remains too small and incomplete to establish effectiveness or routine safety. FDA has not approved BPC-157. A positive advisory signal did not create final authorization.
Direct answer
Interest has moved faster than clinical evidence.
BPC-157 is a synthetic 15-amino-acid peptide studied mainly in laboratory and animal models. FDA’s 2026 review found five small human studies spanning healthy volunteers, ulcerative colitis, knee pain, interstitial cystitis, and intravenous exposure. The studies were short, small, and often provided limited methods or safety detail.
That is different from saying there is no human research. It means the available research cannot support the broad healing, recovery, gastrointestinal, or safety claims commonly made online.
Four evidence lanes that should not be blended.
Confidence depends on study design, sample size, controls, replication, product characterization, and whether the measured outcome matters to patients.
Human clinical evidence
Very limitedFDA identified five small, short studies across several unrelated uses. Most were uncontrolled or available only as abstracts, with limited safety reporting.
What it means: They cannot establish that BPC-157 heals injuries, treats gastrointestinal disease, or is safe for routine or long-term use.
Animal and laboratory evidence
Numerous, but indirectPreclinical studies report effects involving wound repair, tendons, gastrointestinal injury, blood vessels, and inflammatory pathways.
What it means: A biological effect in cells, rats, mice, rabbits, or dogs does not establish a clinically useful benefit in people.
Trial-registry record
Listed as recruiting; credibility unresolvedA sponsor-submitted record describes a randomized hamstring-strain study at one site in Shenzhen, China. It is marked not FDA-regulated and has no posted results. Two other records from the same sponsor explicitly describe themselves as mock or fictional studies.
What it means: The record cannot presently be relied on as confirmation that an operating clinical trial exists. Registration alone never establishes benefit, safety, U.S. regulatory acceptance, or FDA authorization.
Anecdotes and online reports
Common, not controlledPersonal recovery stories cannot separate treatment effects from rehabilitation, natural healing, placebo effects, selection bias, or product differences.
What it means: A compelling story can generate a research question, but it cannot answer one.
Human data
Small studies answer narrow questions—not the headline claim.
FDA’s review described short exposures in approximately 24 healthy volunteers receiving rectal enemas, roughly 26 ulcerative-colitis participants receiving an enema, 17 people receiving knee injections, 12 people receiving an intravesical procedure for interstitial cystitis, and two healthy adults in an intravenous pilot.
No serious adverse events appeared in those reports, but FDA emphasized the small samples, short duration, exploratory designs, limited safety information, and unclear monitoring. A two-person pilot that reports no measured problem cannot rule out uncommon, delayed, route-specific, or long-term harms.
A 2026 sports-medicine scoping review reached a similar high-level conclusion across BPC-157 and several other peptides: the literature was predominantly preclinical, while human evidence remained limited and methodologically weak. A review can summarize the gap, but it cannot repair the underlying absence of robust controlled human trials.
Trial registry
A registry entry is a claim to verify—not proof that a trial is operating.
ClinicalTrials.gov currently displays NCT07437547 as a recruiting Phase 2 BPC-157 study with one listed site in Shenzhen. The record is sponsor-submitted, marked not FDA-regulated, and has no results. ClinicalTrials.gov registration does not mean the U.S. government reviewed the science or verified that recruitment is occurring.
There is an additional credibility problem: two other ClinicalTrials.gov records from the same sponsor explicitly label themselves as a “Mock Study” or a “fictional study.” That does not prove the BPC-157 record is fictional. It does mean the record should not be presented as confirmed active human research without independent verification of the site, investigators, ethics oversight, or enrollment.
Regulatory status
Three different decisions are being compressed into one headline.
- 1FDA staff evaluation
FDA proposed not adding BPC-157 free base or acetate to the 503A Bulks List, citing characterization, effectiveness, safety, impurity, aggregation, and immunogenicity concerns.
- 2Advisory committee recommendation
The committee reportedly recommended inclusion. Advisory recommendations inform FDA but are non-binding and are not drug approvals.
- 3Final agency action
FDA’s meeting page does not currently post a final determination. Until that changes, “the panel voted” and “FDA finalized” remain different statements.
Safety
Unknown does not mean harmless—or proven harmful.
FDA identified incomplete long-term toxicology, possible clotting and liver-related signals in short animal studies, and unresolved concerns about immune responses, peptide aggregation, impurities, and inconsistent chemical naming. FDA also found a small number of adverse-event reports, but said those reports could not establish that BPC-157 caused the events.
Product quality is a separate uncertainty from the molecule itself. A purity number alone does not establish correct identity, dose, sterility, endotoxin control, impurity profile, stability, or clinical safety.
Competitive sport
For tested athletes, the rule is clearer than the clinical evidence.
The 2026 World Anti-Doping Agency Prohibited List names BPC-157 under S0, non-approved substances. That category is prohibited at all times. Athletes should verify the current rule with their governing body or anti-doping organization rather than relying on a clinic, seller, or social-media explanation.
Use the evidence gap to ask better questions.
These questions do not determine treatment. They help make the uncertainty visible in a conversation with a licensed clinician.
- 01
Which specific human study supports the exact condition and outcome being discussed?
- 02
Was the study randomized and controlled, and how many people completed it?
- 03
Is the substance an FDA-approved product, within a conditional compounding policy, or neither?
- 04
How would product identity, sterility, impurities, aggregation, and adverse events be assessed?
- 05
If I compete in sport, what do my governing body and the current WADA list require?
Source trail
Read the records behind the conclusion.
FDA records carry the most weight on U.S. regulatory status. Trial-registry entries are sponsor-submitted records, not agency validation; the linked same-sponsor examples explain why this page now treats the BPC-157 entry as unverified. The Associated Press link is included only for the reported committee vote because FDA’s public meeting page does not currently show vote results.